An International, Multicenter, Placebo-Controlled Trial of Paroxetine in Adolescents with Major Depressive Disorder
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The aim of this study was to examine the efficacy, safety, and tolerability of paroxetine in adolescents with unipolar major depression. METHOD: Two hundred eighty-six (286) adolescents with unipolar major depression were randomly assigned to receive either paroxetine or placebo for 12 weeks. RESULTS: The proportion of Montgomery-Asberg Depression Rating Scale (MADRS) responders (at least 50% reduction from baseline) for paroxetine and placebo were similar and not statistically different at endpoint (p = 0.702). A similar result was obtained for change from baseline on the Kiddie-Schedule for Affective Disorders and Schizophrenia for School- Age Children (K-SADS-L) depression subscale. Among secondary endpoints, only a significantly higher Clinical Global Impression-Improvement (CGI-I) response rate was reported in paroxetine-treated patients versus placebo (69.2% versus 57.3%; p = 0.045). In general, results differed by age, with patients older than 16 years demonstrating a greater response to active treatment. This age group also reported more adverse experiences (AEs) relative to placebo than younger adolescents. Overall, paroxetine was generally well tolerated (11% discontinued owing to an AE versus 7% of placebo-treated patients). A post hoc analysis of AEs related to suicidal behavior suggested a greater incidence of these events for paroxetine than for placebo (4.4% versus 2.1%); however, this difference was not statistically significant (odds ratio, 2.15, 95% Confidence Interval 0.45, 10.33; p = 0.502). CONCLUSIONS: No statistically significant differences were observed for paroxetine compared with placebo on the two prospectively defined primary efficacy variables. Paroxetine at 20-40 mg/day administered over a period of up to 12 weeks was generally well tolerated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Children's Global Assessment Scale (CGAS)
Shaffer, D. (1983) · Archives of General Psychiatry · doi:10.1001/archpsyc.1983.01790100074010 · Cited by 3,716 · cited 2×
“…to have a symptom se-60 verity rating of at least 16 on the Montgomery-Åsberg Depression Rating Scale (MADRS; Montgomery and Åsberg 1979) at screening and baseline and a PAROXETINE IN ADOLESCENTS WITH MDD Children’s Global Assessment Score (C-GAS) of less than 69 (Shaffer et al. 1983) at screening.”
Childhood and adolescent depression: a review of the past 10 years, Part I
BIRMAHER, B., RYAN, N. D., WILLIAMSON, D. E., BRENT, D. A., KAUFMAN, J., DAHL, R. E., PEREL, J., & NELSON, B. (1996) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199611000-00011 · Cited by 2,076
Major Depression in Community Adolescents: Age at Onset, Episode Duration, and Time to Recurrence
LEWINSOHN, P. M., CLARKE, G. N., SEELEY, J. R., & ROHDE, P. (1994) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199407000-00006 · Cited by 836
Brent, D. A. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830210125017 · Cited by 753
KELLER, M. B., RYAN, N. D., STROBER, M., KLEIN, R. G., KUTCHER, S. P., BIRMAHER, B., HAGINO, O. R., KOPLEWICZ, H., CARLSON, G. A., CLARKE, G. N., et al. (2001) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200107000-00010 · Cited by 641
Cited by
Bridge, J. A., Iyengar, S., Salary, C. B., Barbe, R. P., Birmaher, B., Pincus, H. A., Ren, L., & Brent, D. A. (2007) · JAMA · doi:10.1001/jama.297.15.1683 · Cited by 1,086
Cipriani, A., Zhou, X., Del Giovane, C., Hetrick, S. E., Qin, B., Whittington, C., Coghill, D., Zhang, Y., Hazell, P., Leucht, S., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30385-3 · Cited by 734
Locher, C., Koechlin, H., Zion, S. R., Werner, C., Pine, D. S., Kirsch, I., Kessler, R. C., & Kossowsky, J. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.2432 · Cited by 360
“For adultswith DD, a genuine placebo effect has been demonstrated, as the combination of placebo andsupportive carehasbeenshowntobemorebeneficial than supportive care alone.(13) Conversely, patients in the placebo groupalsodemonstrateTEAEs.”
Newer generation antidepressants for depressive disorders in children and adolescents
Hetrick, S. E., McKenzie, J. E., Cox, G. R., Simmons, M. B., & Merry, S. N. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004851.pub3 · Cited by 291
Bridge, J. A., Birmaher, B., Iyengar, S., Barbe, R. P., & Brent, D. A. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08020247 · Cited by 256
“…14.6 54 74 86 Wagner et al. 2004 (21)b Citalopram, 20–40 mg 2001 178 12.0 53 77 81 Wagner et al. 2006 (27)b Escitalopram, 10–20 mg 2004 268 12.3 52 71 — Berard et al. 2006 (28) Paroxetine, 20–40 mg 1998 286 15.6 66 68 70 Emslie et al. 2006 (29) Paroxetine, 10–50 mg 2001 206 12.0 47 79 53 Emslie…”
InfluentialRief, W., Nestoriuc, Y., von Lilienfeld-Toal, A., Dogan, I., Schreiber, F., Hofmann, S. G., Barsky, A. J., & Avorn, J. (2009) · Drug Safety · doi:10.2165/11316580-000000000-00000 · Cited by 202
“A total of 143 studies([14-155]) 2 including 12 742 patients (11 719 in SSRI placebo groups, 1023 in TCA placebo groups) were analysed (see figure 1).”
BackgroundSelective serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and adolescents
Hetrick, S. E., Merry, S. N., McKenzie, J., Sindahl, P., & Proctor, M. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004851.pub2 · Cited by 180
Walkup, J. T. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.16091059 · Cited by 112
Courtney, D. B., Watson, P., Krause, K. R., Chan, B. W. C., Bennett, K., Gunlicks-Stoessel, M., Rodak, T., Neprily, K., Zentner, T., & Szatmari, P. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.46331 · Cited by 63
Rohden, A. I., Benchaya, M. C., Camargo, R. S., Moreira, T. D. C., Barros, H. M. T., & Ferigolo, M. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.03.017 · Cited by 35
Generalizability of Clinical Trial Results for Adolescent Major Depressive Disorder
Blanco, C., Hoertel, N., Franco, S., Olfson, M., He, J.-P., López, S., González-Pinto, A., Limosin, F., & Merikangas, K. R. (2017) · Pediatrics · doi:10.1542/peds.2016-1701 · Cited by 29
Metadata
- Authors
- Berard, R., Fong, R., Carpenter, D. J., Thomason, C., & Wilkinson, C.
- Venue
- Journal of Child and Adolescent Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2006-03
- Volume
- 16
- Issue
- 1-2
- Pages
- 59-75
- ISSN
- 1044-5463 (ISSN-L)
- 1557-8992
- OpenAlex
- W1994910887
- Cited by
- 104
- References
- 5
- FWCI
- 3.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.